Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

NCT00538343 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00538343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00538343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2007
Completion date
January 1, 2009
Enrollment
14 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases